Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation, steatosis, and fibrosis. Sympathetic nerves play a critical role in maintaining hepatic lipid homeostasis and regulating fibrotic progression through adrenergic receptors expressed by hepatocytes and hepatic stellate cells; however, the use of sympathetic nerve-focused strategies for the treatment of NAFLD is still in its infancy. Herein, a biomimetic nanoplatform with ROS-responsive and ROS-scavenging properties was developed for the codelivery of retinoic acid (RA) and the adrenoceptor antagonist labetalol (LA). The nanoplatform exhibited improved accumulation and sufficient drug release in the fibrotic liver, thereby achieving precise codelivery of drugs. Integration of adrenergic blockade effectively interrupted the vicious cycle of sympathetic nerves with hepatic stellate cells (HSCs) and hepatocytes, which not only combined with RA to restore HSCs to a quiescent state but also helped to reduce hepatic lipid accumulation. We demonstrated the excellent ability of the biomimetic nanoplatform to ameliorate liver inflammation, fibrosis, and steatosis. Our work highlights the tremendous potential of a sympathetic nerve-focused strategy for the management of NAFLD and provides a promising nanoplatform for the treatment of NAFLD.
Introduction
Nonalcoholic Fatty Liver Disease (NAFLD) has become a global health crisis, currently affecting approximately 25% of the world's population. The disease progresses through a spectrum of severity, beginning with simple lipid accumulation (steatosis), advancing to inflammation (steatohepatitis), and eventually leading to irreversible scarring (fibrosis) and cirrhosis. While traditional research has focused heavily on metabolic and inflammatory pathways, recent evidence suggests that the sympathetic nervous system (SNS) plays a pivotal role in the disease's progression.
In a diseased liver, sympathetic nerves often become hyperactive, releasing excessive amounts of norepinephrine. This neurotransmitter acts on adrenergic receptors in hepatocytes to promote fat storage and in hepatic stellate cells (HSCs) to trigger fibrotic activation. This creates a "vicious cycle" where diseased liver cells and overactive nerves reinforce each other's pathological states. Addressing this neurological component offers a novel therapeutic avenue for NAFLD management.
Methodology: The Biomimetic Nanoplatform
To address the complexities of NAFLD, researchers developed a sophisticated biomimetic nanoplatform designed for precision delivery and multi-stage therapeutic action. The platform, designated as MSN-SeSe-LA/RA@M-Apt, is engineered with several key components:
- ROS-Responsive Core: The foundation consists of mesoporous silica nanoparticles (MSNs) featuring diselenide (Se-Se) bridges. These bridges are designed to break apart specifically in the presence of reactive oxygen species (ROS), which are highly concentrated in the oxidative environment of a diseased liver. This ensures that the drug payload is released only where it is needed most.
- Biomimetic Coating: The MSNs are encapsulated in a macrophage membrane. This "cloak" allows the nanoparticles to evade the immune system—specifically avoiding clearance by Kupffer cells—and increases their circulation time in the bloodstream.
- Targeting Mechanism: The surface is functionalized with a CD44 aptamer. Activated HSCs, the primary drivers of fibrosis, overexpress the CD44 receptor, allowing the nanoplatform to home in on these specific cells.
- Dual-Drug Payload: The platform co-delivers Retinoic Acid (RA) and Labetalol (LA). RA is a vitamin A metabolite that helps revert activated HSCs to a quiescent (inactive) state, while LA is an adrenergic receptor blocker that interrupts the pathological nerve-signaling loop.
Breaking the Vicious Cycle
The core innovation of this study lies in the "bidirectional influence" between the nervous system and liver cells. The researchers confirmed that norepinephrine acts as an autocrine factor for HSCs, meaning the cells produce the neurotransmitter to stimulate their own activation. By blocking these adrenergic receptors with Labetalol, the nanoplatform effectively "mutes" the cross-talk between the nervous system and the liver tissue.
Furthermore, the diselenide-bridged silica core acts as a therapeutic participant rather than just a carrier. As it reacts with ROS to release the drugs, it simultaneously consumes these harmful molecules, providing an immediate anti-inflammatory benefit by reducing oxidative stress at the site of injury.
Key Results and Therapeutic Efficacy
The platform was validated using two distinct mouse models: the Bile Duct Ligation (BDL) model for advanced fibrosis and a High-Fat Diet (HFD) model for metabolic steatosis. Key findings include:
- Precision Targeting: The nanoplatform showed significantly higher accumulation in fibrotic liver tissue compared to healthy controls, validating the effectiveness of the CD44 aptamer and macrophage coating.
- Fibrosis Reversal: In the BDL model, treatment resulted in a striking reduction in α-SMA (a marker of HSC activation) and collagen deposition, indicating a reversal of the fibrotic process.
- Metabolic and Liver Function Recovery: In HFD mice, the treatment significantly lowered body weight, liver weight, and LDL cholesterol. Crucially, serum markers of liver damage (ALT and AST) were restored to near-normal levels. Quantitative analysis confirmed that the dual-drug platform was superior to single-drug or standard formulations in reducing lipid droplet accumulation.
Conclusion
This study demonstrates that a sympathetic nerve-focused strategy, delivered via a ROS-responsive biomimetic nanoplatform, is a highly effective approach for treating NAFLD. By simultaneously scavenging ROS, reverting HSC activation with RA, and blocking adrenergic signaling with LA, the platform breaks the cycle of disease progression. While further research is needed to transition these findings from mouse models to human clinical trials, this work provides a promising blueprint for the next generation of NAFLD therapies.
Summary updated